Blogs
Healthcare and Medtech Research Reports
Aug 05, 2026
Summary Intra-tumoral cancer therapies involve the direct administration of antitumor agents into tumors, promoting localized tumor destruction, stimulating the release of tumor-associated antigens, and activating an immune response within the tumor microenvironment that may also generate systemic antitumor eff...
Read More...
Nov 27, 2023
The FDA has approved label extensions for two of the most crucial cancer medications globally—Merck’s Keytruda and Pfizer and Astellas’ Xtandi. Keytruda’s expanded indication now includes stomach cancer, permitting its usage alongside chemotherapy for first-line treatment in patients with locally advanced unresecta...
Read More...
Mar 17, 2023
Oncology has become a growing area of interest for pharmaceutical companies over the years. With a significant increase in R&D and healthcare spending worldwide, companies ranging from large pharmaceutical conglomerates to smaller biotech organizations are frantically attempting to capitalize on lucrative marke...
Read More...
Oct 14, 2022
Immune checkpoint inhibitors are drugs that inhibit immune checkpoints. These drugs allow immune cells to respond more strongly to cancer by blocking them. This blocks the “off” signal, allowing T-cells to kill cancer cells. Checkpoint inhibitors can be used to treat a variety of cancers, including lung cancer (...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Newsletter/Whitepaper